A city in eastern China offers an experimental coronavirus vaccine (Covid-19) outside of clinical trials for approximately $ 60 in high-risk groups under an emergency inoculation program, officials said, though experts have expressed concerns over mass launch for a -Upperformed vaccine.
The Beijing-based Sinovac Biotech vaccine is offered in Jiaxing city to care for providers, especially epidemic prevention workers, public service personnel and port inspectors, and will later be offered to regular citizens, state media reported on Friday, citing officials.
“The vaccine, developed by Chinese company Sinovac Biotech, will be given to people aged 18 to 59 for 400 yuan ($ 59.5) for two shots,” the Jiaxing Center for Disease Control and Prevention (CDC) said. , adding that the vaccine has not yet been “officially approved for marketing” and approved only for “urgent needs”.
However, the Jiaxing CDC did not specify what constitutes “urgent needs”.
Authorities also did not say how many people in the city will be vaccinated, coming in two doses between 14-28 days.
The Sinovac vaccine is in the final stages of trials in Brazil, Indonesia and Turkey, and the company said a temporary analysis of test data in phase 3 could come in November, news agency Reuters reported.
In late June, China’s National Health Commission (NHC), under Chinese vaccine management law, allowed emergency vaccines to be used on people at high risk of contracting the deadly virus , including medical workers, frontal demonic control workers and customs. workers – a move that experts consider controversial while vaccines are still in the process. Since July, China has administered such vaccines to hundreds of thousands of people under the program.
On September 25, a leading Chinese health official said Beijing had gained “understanding and support” from the World Health Organization (WHO) before embarking on an emergency use program. In an emailed statement to the HT the next day, the WHO said that China’s decision to launch the program was a home permit. “They are provided at the discretion of the countries and are not subject to WHO approval,” it said.
As of late September, 11 Chinese Covid-19 vaccines had undergone clinical trials, with four in phase 3 clinical trials.
Last week, China announced that it would join COVAX, an international initiative aimed at ensuring universal access to the Covid-19 vaccines, which has become the largest economy supporting the initiative today.
The number of daily Covid-19 cases in mainland China has fallen sharply from the peaks seen in February.
The total number of confirmed cases of Covid-19 in mainland China is over 85,500, while the number of deaths has remained unchanged at 4,634.